The Need for Continued Medical Innovation in Psoriatic Arthritis

In this video produced by the National Psoriasis Foundation, experts offer their insights into improving outcomes for psoriatic arthritis patients.

In this video produced by the National Psoriasis Foundation, experts offer their insights into improving outcomes for psoriatic arthritis patients.

Related Videos
sofiko14 / stock.adobe.com
Mammogram scans | Image credit: okrasiuk - stock.adobe.com
WP_7824 / stock.adobe.com
tilialucida / stock.adobe.com
vectorfusionart / stock.adobe.com
Related Content

FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar

March 21st 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

FDA Approves Trofinetide for Treatment of Rett Syndrome in Adult, Pediatric Patients

March 13th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

FDA Approves Omavaloxolone, the First Drug Indicated for Patients With Friedreich’s Ataxia

March 1st 2023

FDA Approves Sarilumab for Adults With Polymyalgia Rheumatica

March 1st 2023

FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar

March 21st 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

FDA Approves Trofinetide for Treatment of Rett Syndrome in Adult, Pediatric Patients

March 13th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

FDA Approves Omavaloxolone, the First Drug Indicated for Patients With Friedreich’s Ataxia

March 1st 2023

FDA Approves Sarilumab for Adults With Polymyalgia Rheumatica

March 1st 2023

FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar

March 21st 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

FDA Approves Trofinetide for Treatment of Rett Syndrome in Adult, Pediatric Patients

March 13th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

FDA Approves Omavaloxolone, the First Drug Indicated for Patients With Friedreich’s Ataxia

March 1st 2023

FDA Approves Sarilumab for Adults With Polymyalgia Rheumatica

March 1st 2023
© 2023 MJH Life Sciences

All rights reserved.